Navigation Links
PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756
Date:5/23/2013

SCHOFIELD, Wis., May 23, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB: PMBS) a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research re-issued its research opinion on the company based on low market capitalization valuation.

Report Highlights

  • Non-Prescription, All Natural Product to Treat Migraine Headaches
  • Clinical Trials Show the Product Outperforms #1 Prescription Competitor
  • Currently Available Nationwide at Walgreen's and CVS/pharmacy stores
  • Launching Marketing and Distribution Campaign
  • Expanding Retail-Chain-Store Distribution
  • Holds Patent on Product
  • 38 Million Shares Outstanding
  • Market Cap just under $1 Million

Current Valuation
As of May 14, 2013, PuraMed BioScience had approximately 37.9 million common shares outstanding, thus giving the stock a market cap valuation of an estimated $721,756.

PuraMed BioScience currently has LipiGesic® M, an over-the-counter migraine pain reliever, distributed in Walgreens and CVS/pharmacy stores nationwide. The Company plans to expand that retail placement to an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as selected regional drugstore chains.

Revenue Potential
With an estimated 39 million Americans suffering from migraine headaches, the revenue prospects for PuraMed BioScience could be explosive.

"The first thing to consider is that people who suffer the excruciating pain of migraine are actively looking for a product that will relieve their migraine pain and associated symptoms," said Russ Mitchell , CEO of PuraMed BioScience. "The second point to consider is that LipiGesic M has been shown to be highly effective and works as well as the number-one-selling prescription migraine treatment without the severe side effects often caused by chemical compounds. Since it is an OTC product, LipiGesic M is available without a doctor's prescription at far less cost. This availability will be increasingly important as insurance premiums, co-pays and deductibles continue to rise in response to changes prompted by the Affordable Care Act."

Thus, if PMBS gains 1% of the migraine market that would result in approximately 400,000 consumers buying LipiGesic M at a retail price of $19.95; that equates to nearly $8 million in sales.

In addition, consumers with acute migraines that recur two to three times a month who find LipiGesic M an effective migraine relief product would be expected to buy nine (9) boxes per year creating a potential of $72 million in annual sales.

These numbers are calculated based on just 1% of the migraine market.

To view the full report, and access risks, disclosures, and potential outlook visit http://www.wallstreetnewscast.com/profile/pmbs.html

About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic® M, PuraMed BioScience plans to launch LipiGesic® H for tension-type headaches and LipiGesic® PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com

Forward-Looking Statements
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
Melissa Diaz ,
South Street Media, Inc
Phone: (917) 937-8968
Email: info@southstreetmedia.com

 


'/>"/>
SOURCE PuraMed BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO
2. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
3. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
4. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
5. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
6. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
7. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
8. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
9. Ohios Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State
10. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
11. Roka Bioscience Secures $47.5 Million in Series D Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 NanoStruck ... (OTCPink: NSKQB) ( Frankfurt : 8NSK) ... Pressemitteilung vom 13. August 2015 die Genehmigung von ... um zusätzliche 200.000.000 Einheiten auf 400.000.000 Einheiten zu ... bringen. Davon wurden 157.900.000 Einheiten mit dem ersten ...
(Date:4/27/2016)... ... 2016 , ... PathSensors, Inc., a leading environmental testing company, ... assist PathSensors in expanding the use of the company’s CANARY® technology in the ... for the detection of harmful pathogens, including a number of bacteria, viruses, toxins, ...
(Date:4/27/2016)... 27, 2016 MedDay, a biotechnology company ... the appointment of Catherine Moukheibir as Chairman of its Board ... Jean Jacques Garaud , who contributed to the rapid ... immediately. Catherine started her career in strategy consulting ... London .  She held C-Suite level roles ...
(Date:4/26/2016)... ... 2016 , ... The European Patent Office (EPO) today announced that ... for the European Inventor Award 2016 in the category "Non-European countries." The winners of ... ceremony in Lisbon on June 9th. , The human capacity to walk with fluidity ...
Breaking Biology Technology:
(Date:3/14/2016)... Allemagne, March 14, 2016 ... - --> - Renvoi : image disponible ... --> --> DERMALOG, ... fournit de nouveaux lecteurs d,empreintes digitales pour l,enregistrement ... DERMALOG sera utilisé pour produire des cartes d,identité ...
(Date:3/10/2016)... --  Unisys Corporation (NYSE: UIS ) today announced ... testing its biometric identity solution at the Otay Mesa border ... identify certain non-U.S. citizens leaving the country. ... determine the efficiency and accuracy of using biometric technologies in ... until May 2016. --> the United States ...
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
Breaking Biology News(10 mins):